Information Provided By:
Fly News Breaks for June 15, 2018
Jun 15, 2018 | 10:46 EDT
As previously reported, Janney Montgomery Scott analyst Ken Trbovich downgraded Amag Pharmaceuticals to Neutral from Buy after the company announced it has agreed to divest Cord Blood Registry to a private equity investment firm for $530M in cash. The sale loses a positive contributor for the company at a price below which CBR was acquired, said Trbovich, who maintains a $20 fair value estimate on Amag shares, which are down about 5% to $23.60 in morning trading.
News For AMAG From the Last 2 Days
There are no results for your query AMAG
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.